Oncolytics Biotech Inc., a prominent player in the health care biotechnology sector, has been making significant strides in the development of innovative cancer treatments. As a company listed on the Nasdaq, Oncolytics Biotech Inc. operates with a primary focus on discovering and developing pharmaceutical products aimed at treating cancers that have not responded to conventional therapies. The company’s commitment to advancing cancer treatment is exemplified by its pioneering work on REOLYSIN, a reovirus-based therapeutic.
As of September 11, 2025, Oncolytics Biotech Inc. reported a close price of $1.28 per share. The company’s stock has experienced fluctuations over the past year, with a 52-week high of $1.53 on October 6, 2024, and a 52-week low of $0.33 on June 5, 2025. Despite these variations, the company maintains a market capitalization of approximately $128,462,210 USD, reflecting its ongoing efforts and potential in the biotechnology industry.
Founded on November 8, 1999, Oncolytics Biotech Inc. has established itself as a leader in the biotechnology field, particularly in the realm of oncolytic virotherapy. The company’s flagship product, REOLYSIN, is at the forefront of its research and development initiatives. REOLYSIN is designed to selectively target and destroy cancer cells while sparing healthy cells, offering a novel approach to cancer treatment. This therapeutic has the potential to address a wide range of cancers, providing hope for patients who have exhausted other treatment options.
Oncolytics Biotech Inc. is listed on the Toronto Stock Exchange, further solidifying its presence in the global biotechnology market. The company’s dedication to innovation and patient care is evident in its ongoing clinical trials and research efforts. By focusing on the development of REOLYSIN and other potential cancer therapeutics, Oncolytics Biotech Inc. aims to fill the unmet needs in cancer treatment and improve patient outcomes.
For more information about Oncolytics Biotech Inc. and its developments, interested parties can visit the company’s website at www.oncolyticsbiotech.com . As the company continues to advance its research and expand its portfolio of cancer treatments, it remains a key player in the biotechnology sector, committed to making a significant impact on cancer care.